
Group Structure
View All
Industry
Registered Address
c/o mazars, mayoralty house, flood street galway, co galway galway, 999925
Website
-Pomanda estimates the enterprise value of NATIONAL BREAST CANCER RESEARCH INSTITUTE COMPANY LIMITED BY GUARANTEE at €0 based on a Turnover of €2.2m and 0x industry multiple (adjusted for size and gross margin).
Pomanda estimates the enterprise value of NATIONAL BREAST CANCER RESEARCH INSTITUTE COMPANY LIMITED BY GUARANTEE at €0 based on an EBITDA of €-51k and a 0x industry multiple (adjusted for size and gross margin).
Pomanda estimates the enterprise value of NATIONAL BREAST CANCER RESEARCH INSTITUTE COMPANY LIMITED BY GUARANTEE at €0 based on Net Assets of €1.3m and 0x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
National Breast Cancer Research Institute Company Limited By Guarantee is a live company located in flood street galway, 999925 with a Companies House number of IE168740. Founded in January 1991, it's largest shareholder is unknown. National Breast Cancer Research Institute Company Limited By Guarantee is a mature, small sized company, Pomanda has estimated its turnover at €2.2m with high growth in recent years.
There is insufficient data available to calculate a health check for National Breast Cancer Research Institute Company Limited By Guarantee. Company Health Check FAQs
0 Strong
0 Regular
0 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - National Breast Cancer Research Institute Company Limited By Guarantee
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- - National Breast Cancer Research Institute Company Limited By Guarantee
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - National Breast Cancer Research Institute Company Limited By Guarantee
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - National Breast Cancer Research Institute Company Limited By Guarantee
- - Industry AVG
Employees
There is insufficient data available for this Key Performance Indicator!
- - National Breast Cancer Research Institute Company Limited By Guarantee
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- - National Breast Cancer Research Institute Company Limited By Guarantee
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- - National Breast Cancer Research Institute Company Limited By Guarantee
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - National Breast Cancer Research Institute Company Limited By Guarantee
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - National Breast Cancer Research Institute Company Limited By Guarantee
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - National Breast Cancer Research Institute Company Limited By Guarantee
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - National Breast Cancer Research Institute Company Limited By Guarantee
- - Industry AVG
Debt Level
There is insufficient data available for this Key Performance Indicator!
- - National Breast Cancer Research Institute Company Limited By Guarantee
- - Industry AVG
National Breast Cancer Research Institute Company Limited By Guarantee's latest turnover from December 2023 is €2.2 million and the company has net assets of €1.3 million. According to their latest financial statements, National Breast Cancer Research Institute Company Limited By Guarantee has 3 employees and maintains cash reserves of €2.1 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
---|---|---|---|---|---|---|---|---|
Turnover | 2,223,971 | 1,634,967 | 1,296,444 | 1,023,622 | 1,148,644 | 896,646 | 690,548 | 739,964 |
Other Income Or Grants | ||||||||
Cost Of Sales | ||||||||
Gross Profit | ||||||||
Admin Expenses | ||||||||
Operating Profit | 974,813 | 738,244 | 781,238 | 616,641 | 485,155 | 478,928 | ||
Interest Payable | ||||||||
Interest Receivable | 55 | |||||||
Pre-Tax Profit | -1,911 | 311,126 | 324,813 | -225,193 | 316,238 | 166,641 | 165,050 | 5,875 |
Tax | ||||||||
Profit After Tax | -1,911 | 311,126 | 324,813 | -225,193 | 316,238 | 166,641 | 165,050 | 5,875 |
Dividends Paid | ||||||||
Retained Profit | -1,911 | 311,126 | 324,813 | -225,193 | 316,238 | 166,641 | 165,050 | 5,875 |
Employee Costs | 137,261 | 72,441 | 65,237 | 44,518 | 79,740 | 57,349 | 59,712 | 131,403 |
Number Of Employees | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 3 |
EBITDA* | 975,175 | 738,791 | 781,683 | 616,933 | 485,155 | 479,219 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
---|---|---|---|---|---|---|---|---|
Tangible Assets | 2,510 | 2,596 | 362 | 909 | 1,023 | |||
Intangible Assets | ||||||||
Investments & Other | ||||||||
Debtors (Due After 1 year) | ||||||||
Total Fixed Assets | 2,510 | 2,596 | 362 | 909 | 1,023 | |||
Stock & work in progress | ||||||||
Trade Debtors | ||||||||
Group Debtors | ||||||||
Misc Debtors | 3,706 | 26,562 | 13,806 | 90,555 | 49,744 | 26,076 | 60,395 | 54,002 |
Cash | 2,124,054 | 2,340,051 | 1,892,145 | 1,418,873 | 1,283,225 | 954,058 | 505,994 | 619,739 |
misc current assets | ||||||||
total current assets | 2,127,760 | 2,366,613 | 1,905,951 | 1,509,428 | 1,332,969 | 980,134 | 566,389 | 673,741 |
total assets | 2,130,270 | 2,369,209 | 1,905,951 | 1,509,790 | 1,333,878 | 981,157 | 566,389 | 673,741 |
Bank overdraft | ||||||||
Bank loan | ||||||||
Trade Creditors | 841 | 554 | 8,797 | 383 | ||||
Group/Directors Accounts | ||||||||
other short term finances | ||||||||
hp & lease commitments | ||||||||
other current liabilities | 41,106 | 423,968 | 386,754 | 377,415 | 260,570 | 216,677 | 9,246 | 2,992 |
total current liabilities | 41,947 | 424,522 | 386,754 | 386,212 | 260,570 | 216,677 | 9,246 | 3,375 |
loans | ||||||||
hp & lease commitments | ||||||||
Accruals and Deferred Income | ||||||||
other liabilities | ||||||||
provisions | 832,927 | 687,380 | 573,016 | 502,210 | 226,747 | 234,157 | 193,461 | 471,734 |
total long term liabilities | 832,927 | 687,380 | 573,016 | 502,210 | 226,747 | 234,157 | 193,461 | 471,734 |
total liabilities | 874,874 | 1,111,902 | 959,770 | 888,422 | 487,317 | 450,834 | 202,707 | 475,109 |
net assets | 1,255,396 | 1,257,307 | 946,181 | 621,368 | 846,561 | 530,323 | 363,682 | 198,632 |
total shareholders funds | 1,255,396 | 1,257,307 | 946,181 | 621,368 | 846,561 | 530,323 | 363,682 | 198,632 |
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
---|---|---|---|---|---|---|---|---|
Operating Activities | ||||||||
Operating Profit | 974,813 | 738,244 | 781,238 | 616,641 | 485,155 | 478,928 | ||
Depreciation | 1,124 | 352 | 362 | 547 | 445 | 292 | 291 | |
Amortisation | ||||||||
Tax | ||||||||
Stock | ||||||||
Debtors | -22,856 | 12,756 | -76,749 | 40,811 | 23,668 | -34,319 | 6,393 | 54,002 |
Creditors | 287 | 554 | -8,797 | 8,797 | -383 | 383 | ||
Accruals and Deferred Income | -382,862 | 37,214 | 9,339 | 116,845 | 43,893 | 207,431 | 6,254 | 2,992 |
Deferred Taxes & Provisions | 145,547 | 114,364 | 70,806 | 275,463 | -7,410 | 40,696 | -278,273 | 471,734 |
Cash flow from operations | 1,123,272 | 1,099,085 | 794,498 | 899,379 | 206,360 | 900,326 | ||
Investing Activities | ||||||||
capital expenditure | -1,315 | |||||||
Change in Investments | ||||||||
cash flow from investments | -1,315 | |||||||
Financing Activities | ||||||||
Bank loans | ||||||||
Group/Directors Accounts | ||||||||
Other Short Term Loans | ||||||||
Long term loans | ||||||||
Hire Purchase and Lease Commitments | ||||||||
other long term liabilities | ||||||||
share issue | ||||||||
interest | 55 | |||||||
cash flow from financing | 192,812 | |||||||
cash and cash equivalents | ||||||||
cash | -215,997 | 447,906 | 473,272 | 135,648 | 329,167 | 448,064 | -113,745 | 619,739 |
overdraft | ||||||||
change in cash | -215,997 | 447,906 | 473,272 | 135,648 | 329,167 | 448,064 | -113,745 | 619,739 |
Perform a competitor analysis for national breast cancer research institute company limited by guarantee by selecting its closest rivals, whether from the industry sector, other small companies, companies in Region Area area or any other competitors across 12 key performance metrics.
NATIONAL BREAST CANCER RESEARCH INSTITUTE COMPANY LIMITED BY GUARANTEE group structure
National Breast Cancer Research Institute Company Limited By Guarantee has no subsidiary companies.
Ultimate parent company
NATIONAL BREAST CANCER RESEARCH INSTITUTE COMPANY LIMITED BY GUARANTEE
IE168740
National Breast Cancer Research Institute Company Limited By Guarantee currently has 12 directors. The longest serving directors include ANTHONY RYAN (Apr 2013) and LOURDA MCHUGH (Apr 2013).
officer | country | age | start | end | role |
---|---|---|---|---|---|
ANTHONY RYAN | 67 years | Apr 2013 | - | Director | |
LOURDA MCHUGH | 63 years | Apr 2013 | - | Director | |
MICHAEL WALSH | 60 years | Apr 2013 | - | Director | |
TIMOTHY O'BRIEN | 64 years | Feb 2015 | - | Director | |
PATRICIA MCLOUGHLIN | 42 years | Nov 2016 | - | Director | |
GERALDINE LALLY | 62 years | Mar 2017 | - | Director | |
PAUL EARLEY | 60 years | Mar 2017 | - | Director | |
MARIA NOLAN | 66 years | May 2017 | - | Director | |
CAROLINE LOUGHNANE | 52 years | Nov 2019 | - | Director | |
PHILLIP DUFFY | 62 years | Nov 2019 | - | Director |
P&L
December 2023turnover
2.2m
+36%
operating profit
-52.1k
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
1.3m
0%
total assets
2.1m
-0.1%
cash
2.1m
-0.09%
net assets
Total assets minus all liabilities
Similar Companies
company number
IE168740
Type
CLG - COMPANY LIMITED BY GUARANTEE
industry
incorporation date
January 1991
age
34
incorporated
IE
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
national breast cancer research institute limited (January 1991)
accountant
-
auditor
FORVIS MAZARS
address
c/o mazars, mayoralty house, flood street galway, co galway galway, 999925
Bank
BANK OF IRELAND
Legal Advisor
FORDE & ASSOCIATES
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to national breast cancer research institute company limited by guarantee.
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NATIONAL BREAST CANCER RESEARCH INSTITUTE COMPANY LIMITED BY GUARANTEE. This can take several minutes, an email will notify you when this has completed.
date | description | view/download |
---|